DRRX

Durect Corp

$1.36

chg

-0.02 (-1.45%)

quotes and stock data may be delayed 15 minutes

52 wk low

1.28

52 wk hi

2.95

Cash

$104.8M

Burn Rate (Qtr)

$9.6M

Mkt Cap

$309.3m

Avg Volume

592,995

*cash/burn updated:

Q1 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

DRRX

BPIQ_Logo_RGB-01.jpg

Company Profile

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH).

Recent Posts

See what the community is saying - click to see full post.

Biopharma Stock Updates - 12/07/2020